Sugi Predict

Sugi Predict / Compounds / SCHEMBL1014920

SCHEMBL1014920

SCHEMBL1014920

Nc1nc(N)c2cn[nH]c2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ XDH P47989 2/20 0.55
▸ RET P07949 1/20 0.55
▸ PI4KA P42356 1/20 0.55
▸ LRRK2 Q5S007 1/20 0.55
▸ PI4K2B Q8TCG2 1/20 0.55
▸ PI4K2A Q9BTU6 1/20 0.55
▸ PI4KB Q9UBF8 1/20 0.55
▸ ADORA2A P29274 2/20 0.50
▸ ADORA1 P30542 1/20 0.50
▸ CDK2 P24941 1/20 0.45
▸ CHEK1 O14757 2/20 0.38
▸ DCPS Q96C86 1/20 0.38
▸ PDPK1 O15530 2/20 0.37
▸ DHFR P00374 4/20 0.37
▸ AURKA O14965 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ RAB9A P51151 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29487078 1.00 XDH (0.55) XDHRETPI4KALRRK2PI4K2B
Benzene SCHEMBL25427466 0.96 RET (0.52) XDHRETPI4KALRRK2PI4K2B
SCHEMBL14570604 0.79 ADORA2A (0.47) XDHRETPI4KALRRK2PI4K2B
SCHEMBL341706 0.79 ADORA2A (0.47) XDHRETPI4KALRRK2PI4K2B
SCHEMBL2629520 0.79 ADORA2A (0.47) XDHRETPI4KALRRK2PI4K2B
SCHEMBL888387 0.79 ADORA2A (0.47) XDHRETPI4KALRRK2PI4K2B
SCHEMBL19891462 0.79 ADORA2A (0.47) XDHRETPI4KALRRK2PI4K2B
SCHEMBL560806 0.79 RET (0.52) XDHRETPI4KALRRK2PI4K2B
SCHEMBL95123 0.79 XDH (0.52) XDHRETPI4KALRRK2PI4K2B
SCHEMBL95394 0.79 XDH (0.52) XDHRETPI4KALRRK2PI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023071218-A1 PYRAZOLOPYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 沈阳药科大学 2023-05-04 — — WO claimed
EP-3986568-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY Storm Therapeutics Ltd (GB) 2022-04-27 — — EP claimed
WO-2020254831-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OFBCDIN3D ACTIVITY STORM THERAPEUTICS LTD (GB) 2020-12-24 — — WO claimed
US-8957081-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2015-02-17 — — US claimed
US-20130005748-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2013-01-03 — — US claimed
EP-2271630-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2011-01-12 — — EP claimed
WO-2009126515-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-10-15 — — WO claimed
EP-2091918-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-08-26 — — EP claimed
WO-2009032694-A1 AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS DANA FARBER CANCER INSTITUTE (US) 2009-03-12 — — WO claimed
WO-2008073687-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-06-19 — — WO claimed
WO-2008039359-A2 BICYCLIC PYRIMIDINE KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-03 — — WO claimed
US-20040203050-A1 Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression REICH NORBERT (US) 2004-10-14 — — US claimed
US-20240294532-A1 SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS GALDERMA HOLDING S.A. (CH) 2024-09-05 — — US disclosed
EP-4370517-A1 SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS Galderma Holding SA (CH) 2024-05-22 — — EP disclosed
WO-2024061118-A1 MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR 科辉智药生物科技（无锡）有限公司 2024-03-28 — — WO disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
EP-0034945-B1 N-PHENYLPYRAZOLE DERIVATIVES MAY & BAKER LIMITED (GB) 1985-08-07 — — EP disclosed
US-4505740-A Herbicidal 5-amino-4-cyano-1-phenyl-pyrazoles MAY & BAKER LIMITED (GB) 1985-03-19 — — US disclosed
US-4496390-A WEED-CONTRTOLLING HERBICIDES MAY & BAKER LIMITED (GB) 1985-01-29 — — US disclosed
EP-0034945-A2 N-phenylpyrazole derivatives MAY & BAKER LIMITED (GB) 1981-09-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A XDH 2527/4885RET 484/4885PI4KA 156/4885
US-20130005748-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ZAP70, IGF1R, PTK2 XDH 4145/4885RET 397/4885PI4KA 98/4885
US-20240294532-A1 SYNTHESIS OF CHIRAL SUBSTITUTED PYRAZOLOPYRIMIDINE COMPOUNDS MTOR, RICTOR, MLST8 XDH 3644/4885RET 1199/4885PI4KA 93/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.